Literature DB >> 16849456

The thymus plays a role in oral tolerance in experimental autoimmune encephalomyelitis.

Fei Song1, Zhen Guan, Ingrid E Gienapp, Todd Shawler, Jacqueline Benson, Caroline C Whitacre.   

Abstract

The oral administration of myelin proteins has been used for the successful prevention and treatment of experimental autoimmune encephalomyelitis (EAE). We questioned whether the thymus was involved in oral tolerance. In this study, euthymic myelin basic protein (MBP) TCR transgenic mice are protected from EAE when fed MBP but are not protected when thymectomized. Similarly, in a cell transfer system, T cell responses to OVA measured in vivo were suppressed significantly only in the OVA-fed euthymic mice but not in the thymectomized mice. We observed that the absence of the thymus dramatically enhanced the Th1 response. We explored three alternatives to determine the role of the thymus in oral tolerance: 1) as a site for the induction of regulatory T cells; 2) a site for deletion of autoreactive T cells; or 3) a site for the dissemination of naive T cells. We found that Foxp3(+)CD4(+)CD25(+) T cells are increased in the periphery but not in the thymus after Ag feeding. These CD4(+)CD25(+) T cells also express glucocorticoid-induced TNFR and intracellular CTLA4 and suppress Ag-specific proliferation of CD4(+)CD25(-) cells in vitro. The thymus also plays a role in deletion of autoreactive T cells in the periphery following orally administered MBP. However, thymectomy does not result in homeostatic proliferation and the generation of memory cells in this system. Overall, the oral administration of MBP has a profound effect on systemic immune responses, mediated largely by the generation of regulatory T cells that act to prevent or suppress EAE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849456     DOI: 10.4049/jimmunol.177.3.1500

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance.

Authors:  Husein Hadeiba; Katharina Lahl; Abdolhossein Edalati; Cecilia Oderup; Aida Habtezion; Russell Pachynski; Linh Nguyen; Asma Ghodsi; Sarah Adler; Eugene C Butcher
Journal:  Immunity       Date:  2012-03-23       Impact factor: 31.745

2.  Molecular and cellular mechanisms of Mycobacterium avium-induced thymic atrophy.

Authors:  Margarida Borges; Palmira Barreira-Silva; Manuela Flórido; Michael B Jordan; Margarida Correia-Neves; Rui Appelberg
Journal:  J Immunol       Date:  2012-08-24       Impact factor: 5.422

Review 3.  Oral tolerance.

Authors:  Howard L Weiner; Andre Pires da Cunha; Francisco Quintana; Henry Wu
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 4.  Oral tolerance.

Authors:  Ana M C Faria; Howard L Weiner
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

5.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

Review 6.  Tolerance has its limits: how the thymus copes with infection.

Authors:  Cláudio Nunes-Alves; Claudia Nobrega; Samuel M Behar; Margarida Correia-Neves
Journal:  Trends Immunol       Date:  2013-07-16       Impact factor: 16.687

Review 7.  Mechanisms of Oral Tolerance.

Authors:  Scott P Commins
Journal:  Pediatr Clin North Am       Date:  2015-09-07       Impact factor: 3.278

8.  Recent thymic emigrants are the preferential precursors of regulatory T cells differentiated in the periphery.

Authors:  Ricardo S Paiva; Andreia C Lino; Marie-Louise Bergman; Iris Caramalho; Ana E Sousa; Santiago Zelenay; Jocelyne Demengeot
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

9.  Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.

Authors:  Mark D Mannie; J Lori Blanchfield; S M Touhidul Islam; Derek J Abbott
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

10.  Coexistence of primary sclerosing cholangitis in a patient with myasthenia gravis.

Authors:  P J Lorenzoni; R H Scola; C S K Kay; D A Muzzillo; L C Werneck
Journal:  Ann Indian Acad Neurol       Date:  2011-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.